GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (STU:E2Z) » Definitions » Capex-to-Revenue

Almirall (STU:E2Z) Capex-to-Revenue : -0.32 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Almirall Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Almirall's Capital Expenditure for the three months ended in Sep. 2024 was €73.62 Mil. Its Revenue for the three months ended in Sep. 2024 was €230.38 Mil.

Hence, Almirall's Capex-to-Revenue for the three months ended in Sep. 2024 was -0.32.


Almirall Capex-to-Revenue Historical Data

The historical data trend for Almirall's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Capex-to-Revenue Chart

Almirall Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.10 0.09 0.14 0.18

Almirall Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 0.57 0.07 0.42 -0.32

Competitive Comparison of Almirall's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Almirall's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Almirall's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Almirall's Capex-to-Revenue falls into.



Almirall Capex-to-Revenue Calculation

Almirall's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-159.304) / 894.516
=0.18

Almirall's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (73.616) / 230.382
=-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Almirall  (STU:E2Z) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Almirall Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Almirall's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Almirall Business Description

Traded in Other Exchanges
Address
Ronda General Mitre 151, Barcelona, ESP, 08022
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall Headlines

No Headlines